Nov 25, 2019 / 03:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome, everyone, to Medicenna's key opinion leader call focused on its MDNA55 recurrent glioblastoma program and latest Phase IIb clinical study results. (Operator Instructions) As a reminder, today's conference is being recorded.
Before we begin, I would like to remind you that except for historical information, this presentation contains forward-looking statements which reflect Medicenna's current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Medicenna's actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approval and that the risks detailed from time to time in our ongoing quarterly and annual information form available on the company's website.
This forward-looking statement is also based on a number of assumptions, which may prove to be incorrect. Forward-looking
Medicenna Therapeutics Corp to Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results Transcript
Nov 25, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers